---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-050715"
form_type: "8-K"
ticker: "ZURA"
cik: "0001855644"
company_name: "Zura Bio Ltd"
filed_at: "2025-05-20T23:59:59+00:00"
generated_at: "2026-05-21T00:27:52.640598+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Zura Bio launches global Phase 2 TibuSHIELD study of tibulizumab in hidradenitis suppurativa

## Summary
- TibuSHIELD will enroll ~180 adults with moderate-to-severe HS across US, Canada, and Europe.
- Study is 28-week, double-blind, placebo-controlled, with 16-week primary efficacy and 12-week safety follow-up, plus optional OLE.
- Primary endpoint: percent change in total abscess and nodule count at Week 16; secondary endpoints include HiSCR50/75.
- Topline results for primary endpoint expected in Q3 2026.
- Tibulizumab targets both BAFF and IL-17A pathways; still investigational, not FDA-approved.

## SEC filing metadata
- accession: 0001104659-25-050715
- form_type: 8-K
- ticker: ZURA
- cik: 0001855644
- company_name: Zura Bio Ltd
- filed_at: 2025-05-20T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855644/000110465925050715/0001104659-25-050715-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855644/000110465925050715/tm2515452d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-050715
- JSON: https://secwatch.observer/filing/0001104659-25-050715.json
- Plain text: https://secwatch.observer/filing/0001104659-25-050715.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.